Lantern Pharma Strengthens Board with Appointment of Dr. Lee T. Schalop to Advance AI-Driven Oncology Research

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company at the forefront of using artificial intelligence and genomic data to revolutionize oncology drug discovery, has announced the addition of Dr. Lee T. Schalop to its Board of Directors. Dr. Schalop, renowned for his role as co-founder and former CEO of Oncoceutics Inc., brings a wealth of experience in biotechnology leadership and financial markets, particularly in the development of targeted therapies for challenging cancers such as HK327M-mutant gliomas.

The appointment of Dr. Schalop is a strategic move for Lantern Pharma, as his expertise in neurooncology and his successful track record in strategic transactions, including the sale of Oncoceutics to Chimerix Inc. and later to Jazz Pharmaceuticals, aligns with the company's mission to leverage AI for accelerating the development of novel cancer therapies. Lantern CEO Panna Sharma highlighted the significance of Dr. Schalop's joining, noting his potential to contribute to the company's AI-powered drug development platform and its CNS cancer pipeline through Starlight Therapeutics.

Dr. Schalop expressed his enthusiasm for the opportunity to support Lantern Pharma in advancing its precision oncology programs, aiming to bring new hope to patients with limited treatment options. This collaboration underscores Lantern Pharma's commitment to transforming the landscape of cancer treatment by combining cutting-edge AI technology with deep scientific expertise.